SGLT2-Is and MRAs combo associated with lower albuminuria in patients with type 2 DM

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2023-01-20 14:30 GMT | Update On 2023-01-21 09:59 GMT

Combination therapy with SGLT2-Is and MRAs is associated with lower albuminuria in patients with type 2 DM compared to monotherapy with SGLT2-Is or MRAs alone suggests a new study published in Diabetes, Obesity and MetabolismDiabetes mellitus (DM) is the leading cause of chronic kidney disease. Albuminuria is associated with an increased risk of cardiovascular mortality....

Diabetes mellitus (DM) is the leading cause of chronic kidney disease. Albuminuria is associated with an increased risk of cardiovascular mortality. Sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) and mineralocorticoid receptor antagonists (MRAs) protect against albuminuria; however, their combined effects on albuminuria are unclear. We performed a network meta-analysis to investigate the effects of SGLT2-Is, MRAs, and their combination on albuminuria in type 2 DM.

They systematically searched PubMed, Medline, EMBASE, and the Cochrane Library from inception up to November 20, 2022. We selected randomized control and crossover trials that compared MRAs, SGLT2-Is, MRAs + SGLT2-Is, or a placebo in patients with type 2 DM with a urinary albumin-creatinine ratio (UACR) ≥ 30 mg/g creatinine. The primary outcome was the change in the UACR.

Results

• This meta-analysis analyzed 17 studies with 34,412 patients.

• The use of combination treatment with SGLT2-Is and MRAs was associated with lower albuminuria compared to the use of SGLT2-Is, MRAs, or the placebo alone

• Treatment with SGLT2-Is or MRAs alone caused a significant reduction in UACR compared to the placebo

• The effects of MRAs on the UACR are comparable to those of SGLT2-Is. Sensitivity analyses showed similar results.

Combination therapy with SGLT2-Is and MRAs was associated with lower albuminuria in patients with type 2 DM compared to monotherapy with SGLT2-Is or MRAs alone.

Reference:

Morita, R., Tsukamoto, S., Obata, S., Yamada, T., Uneda, K., Uehara, T., Rehman, M.E., Azushima, K., Wakui, H. and Tamura, K. (2023), Effects of sodium-glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and their combination on albuminuria in diabetic patients. Diabetes Obes Metab. Accepted Author Manuscript. https://doi.org/10.1111/dom.14976

Keywords:

Diabetes, Obesity and Metabolism, Morita, R., Tsukamoto, S., Obata, S., Yamada, T., Uneda, K., Uehara, T., Rehman, M.E., Azushima, K., Wakui, H. and Tamura, K, Effects, sodium-glucose, cotransporter 2 inhibitors, mineralocorticoid, receptor antagonists, combination, albuminuria, diabetic patients.

Article Source : Diabetes, Obesity and Metabolism

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Dr. Shravani Dali

Dr. Shravani Dali has completed her BDS from Pravara institute of medical sciences, loni. Following which she extensively worked in the healthcare sector for 2+ years. She has been actively involved in writing blogs in field of health and wellness. Currently she is pursuing her Masters of public health-health administration from Tata institute of social sciences. She can be contacted at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

SGLT2-Is and MRAs combo associated with lower albuminuria in patients with type 2 DM

Similar News